Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H12ClN3.HNO3 |
Molecular Weight | 272.688 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[N+]([O-])=O.CC1=CC=C(NC2=NCCN2)C(Cl)=C1
InChI
InChIKey=SEIGDXGATKHXKR-UHFFFAOYSA-N
InChI=1S/C10H12ClN3.HNO3/c1-7-2-3-9(8(11)6-7)14-10-12-4-5-13-10;2-1(3)4/h2-3,6H,4-5H2,1H3,(H2,12,13,14);(H,2,3,4)
Tolonidine, 2(2-chloro-p-toluidino)-2-imidazoline-nitrate, is a substance chemically related to clonidine. In the anesthetized dog, tolonidine administered i.v. decreased the amplitude of ventricular contractions, reduced aortic blood flow and increased peripheral vascular resistances. In the bivagotomized pithed rat, tolonidine induced a long-lasting increase in blood pressure with no secondary hypotension, thus suggesting peripheral sympathomimetic properties, however, contractions of seminal vesicles in vitro were not obtained. The product proved to have no peripheral sympatholytic or parasympatholytic properties.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093864 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3797809 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline-nitrate (tolonidine), a new antihypertensive agent. III. Action on the secretions of the digestive tract and on the central nervous system, acute toxicity. | 1975 |
|
Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline-nitrate (tolonidine), a new antihypertensive agent. II. Action on cardiac contraction, circulatory parameters, autonomic receptors and diuresis. | 1975 Nov |
|
Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline-nitrate (Tolonidine), a new antihypertensive agent. I. Action on blood pressure and heart rate. | 1975 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3797809
The rats: systemic administration of tolonidine in rats (0.05-5.0 umol/Kg) produced behavioural and electrocortical slow-wave sleep lasting between 35 and 200 min depending on the dose. In addition, a dose-dependent fall in deep body temperature was observed. Similar effects were evoked by infusing tolonidine (5-80 nmol) into the third cerebral ventricle.
Route of Administration:
Intraperitoneal
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
260-785-2
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
SUB04910MIG
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
100000084636
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
m971
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
198360
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
75W1B0GTHA
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
57524-15-9
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD